Ultragenyx gets FDA approval for Fayuvi in Sanfilippo A
FDA approved Ultragenyx’s Fayuvi for children with Sanfilippo syndrome type A, following a 13% stock gain to $14.50 at Thursday’s close.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.